A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study

Wei-Sen Lam; Anna K. Nowak; Fred Chen; Sanjeevan Muruganandan; Sukyana Arunachalam; Melvin Loong; Michael Millward; Kevin Murray; Cathy Read; Jenette Creaney; Gary Y. C. Lee

A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study

Wei-Sen Lam, Anna K. Nowak, Fred Chen, Sanjeevan Muruganandan, Sukyana Arunachalam, Melvin Loong, Michael Millward, Kevin Murray, Cathy Read, Jenette Creaney, Gary Y. C. Lee

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	84-84
Number of pages	1
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	14
Publication status	Published - Nov 2018

Cite this

Lam, W.-S., Nowak, A. K., Chen, F., Muruganandan, S., Arunachalam, S., Loong, M., Millward, M., Murray, K., Read, C., Creaney, J., & Lee, G. Y. C. (2018). A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study. Asia-Pacific Journal of Clinical Oncology, 14, 84-84.

@article{507542859280497c87f004abd42f9e27,

title = "A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study",

author = "Wei-Sen Lam and Nowak, {Anna K.} and Fred Chen and Sanjeevan Muruganandan and Sukyana Arunachalam and Melvin Loong and Michael Millward and Kevin Murray and Cathy Read and Jenette Creaney and Lee, {Gary Y. C.}",

year = "2018",

month = nov,

language = "English",

volume = "14",

pages = "84--84",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "John Wiley & Sons",

}

Lam, W-S, Nowak, AK , Chen, F, Muruganandan, S, Arunachalam, S, Loong, M, Millward, M , Murray, K , Read, C , Creaney, J & Lee, GYC 2018, 'A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. 84-84.

A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study. / Lam, Wei-Sen; Nowak, Anna K.; Chen, Fred et al.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 14, 11.2018, p. 84-84.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma

T2 - final results of the FRAME study

AU - Lam, Wei-Sen

AU - Nowak, Anna K.

AU - Chen, Fred

AU - Muruganandan, Sanjeevan

AU - Arunachalam, Sukyana

AU - Loong, Melvin

AU - Millward, Michael

AU - Murray, Kevin

AU - Read, Cathy

AU - Creaney, Jenette

AU - Lee, Gary Y. C.

PY - 2018/11

Y1 - 2018/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000449544200094&DestLinkType=FullRecord&DestApp=WOS

M3 - Abstract/Meeting Abstract

SN - 1743-7555

VL - 14

SP - 84

EP - 84

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

ER -

A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study

Other files and links

Cite this